---
schema_version: "secwatch.filing_event.v1"
accession: "0001741830-24-000070"
form_type: "8-K"
ticker: null
cik: "0001741830"
company_name: "Kronos Bio, Inc."
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T14:54:33.436766+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kronos Bio cuts 83% of workforce; CEO Bischofberger resigns, Knobelman named interim CEO

## Summary
- Board approved ~83% workforce reduction expected to be substantially completed by Dec 31, 2024.
- Company expects $3.7M charge for severance and benefits; payments substantially complete by Q1 2025.
- CEO Norbert Bischofberger resigns effective Dec 3, 2024; receives $899K special transaction bonus.
- CFO/COO Deborah Knobelman appointed President and Interim CEO; salary raised to $525K, bonus target 50%.
- Knobelman also eligible for $300K special transaction bonus upon change in control.

## SEC filing metadata
- accession: 0001741830-24-000070
- form_type: 8-K
- cik: 0001741830
- company_name: Kronos Bio, Inc.
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/0001741830-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/kron-20241122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001741830-24-000070
- JSON: https://secwatch.observer/filing/0001741830-24-000070.json
- Plain text: https://secwatch.observer/filing/0001741830-24-000070.txt

## Key facts
- Executive change
  Deborah Knobelman was appointed as President and Interim Chief Executive Officer at Kronos Bio, Inc..
  - Action: appointed
  - Role: President and Interim Chief Executive Officer
  source text: On November 22, 2024, Deborah Knobelman, Ph.D., the Company’s Chief Financial Officer and Chief Operating Officer, was appointed to serve as President and Interim Chief Executive Officer, effective December 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/0001741830-24-000070-index.htm
- Executive change
  Norbert Bischofberger resigned as President and Chief Executive Officer at Kronos Bio, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On November 22, 2024, Norbert Bischofberger, Ph.D., resigned as the Company’s President and Chief Executive Officer, effective December 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/0001741830-24-000070-index.htm
- Restructurings & Charges
  Kronos Bio, Inc. announced a restructuring with charges of approximately $3.7 million (approximately 83% reduction in its workforce).
  - Type: restructuring
  - Charge: approximately $3.7 million
  - Headcount: approximately 83% reduction in its workforce
  source text: On November 22, 2024, the Board of Directors (the “Board”) of Kronos Bio, Inc. (the “Company”) approved an approximately 83% reduction in its workforce as part of a strategic resource allocation and cost containment plan. The workforce reduction is expected to be substantially completed on December 31, 2024. In connection with the reduction in workforce, the Company expects to incur a charge of approximately $3.7 million relating to the cash-based expense of the employee severance, benefits, and related costs. The Company anticipates payments associated with the workforce reduction will be substantially complete by the end of the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/0001741830-24-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.